Navigation Links
Increased cancer risk following the use of radioactive Radium-224 in the therapy
Date:6/23/2008

Ankylosing Spondylitis (Bechterew's Disease) is a painful chronic inflammatory rheumatic disease, associated with stiffening of the vertrebral column. Between 100,000 and 150,000 cases have already been diagnosed in Germany, but milder forms of the disease may remain undiagnosed.

The research team, led by Dr. Roland R. Wick, with Dr. Elke A. Nekolla, Prof. Dr. Albrecht M. Kellerer and the late Prof. Dr. Wolfgang Gssner have conducted a long-term follow-up study of 1,471 ankylosing spondylitis patients, whose disease symptoms were treated with repeated intravenous injections of 224Radium. A control cohort of 1,324 ankylosing spondylitis patients treated without the use of radioactive compounds and/or X-rays were also studied.

In the current publication an elevated rate of leukaemias was seen, a malignant disease of the haematopoietic system: In all, 19 observed cases of leukaemia were documented compared with 6.8 cases that would be expected in an age- and gender-matched cohort of a normal population. In particular, the incidence of acute myeloid leukaemia was significantly increased with 7.0 cases compared with 1.8 cases expected in a "normal" population.

Furthermore, four additional cases of preleukaemic diseases of the bone marrow were present in the exposed group and no cases in the control group. The frequency of leukaemia was not increased significantly in the control group compared with the expected value for a normal population.

"It is rather unlikely that impurities present in the radium preparations used before 1950 are responsible for the elevated appearance of myeloproliferative diseases in the exposed group observed here," commented Dr. Roland R. Wick. "In addition, the increased incidence of leukaemia is in line with experimental observations involving the treatment of animals with similar alpha emitting radioisotopes."

The results of these studies by the Helmholtz Zentrum Mnchen have contributed decisively to 224Radium preparations being declared obsolete and have resulted in the revocation of the licensing of SpondylAT by the Federal Institute for Drugs and Medical Devices (BfArM) and the decision by the licence holders to discontinue development of the treatment. In earlier legal proceedings the Cologne Administrative Court, in its decision of October 26th, 2006, came to the conclusion that the "increase of myeloid leukaemia [] could be explained causally with the deposition of radium as a calcium-like element into the bone", because, due to its short half-life of only 3.66 days, the radiation released from 224Radium has its effect mainly at the bone surface in the proximity of the blood-forming bone marrow cells.

Although previous studies have shown that radium treatment has an analgesic effect the risks of 224Radium treatment exceed its benefit, particularly, since there are many other therapeutic options available. Accordingly, the Committee for Quality Assurance of the German Society for Rheumatology no longer include this therapy in its recommendations.


'/>"/>

Contact: Dr. Roland R. Wick
wick@helmholtz-muenchen.de
49-893-187-2518
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related medicine news :

1. Sangui BioTech Files Three 2007 Quarterly Reports, Sales Increased, Losses Continue
2. New Survey Demonstrates Increased Awareness of the Dangers of Meth Use
3. Decreased total sleep time associated with increased REM sleep during subsequent naps
4. Glaucoma report points to increased costs
5. Increased incidence of melanoma found in rheumatoid arthritis patients treated with methotrexate
6. Report confirms increased risk of smoking, substance abuse in bipolar adolescents
7. Fatty liver linked to increased risk of diabetic kidney disease
8. Microsoft HealthVault Be Well Fund Increased to $4.5 Million
9. Unilens Vision Reports Increased Royalty Income
10. Increased screening may better predict those at higher risk for heart disease, researchers report
11. Cumulative radiation exposure shows increased cancer risk for emergency department patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... PIXACORE , an ... one of the Top 100 agencies of the year by MM&M. , This is ... issue, marking an important milestone for the agency. PIXACORE’s newfound recognition reflects its ...
(Date:8/21/2017)... ... August 21, 2017 , ... The Industrial Designers Society of ... 2017 Ceremony and Gala on Aug. 19, 2017 in Atlanta, GA—revealing which 25 ... most prestigious and rigorous design competitions. See all the winners at http://www.idsa.org/awards/idea/gallery . ...
(Date:8/20/2017)... ... , ... Are you an adult with gluten intolerance or Celiac disease living ... in participating in a research study that focuses on family interactions when dealing with ... relational aspects of adults who have gluten sensitivities who cohabitate with other adults who ...
(Date:8/19/2017)... ... August 18, 2017 , ... President Donald Trump signed into ... provides for greater public access to over-the-counter (OTC) hearing aids. , The measure ... aids without being seen by a certified and licensed audiologist. , “The ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... 17, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... and non-U.S. investors for the sale of shares ... the Company,s newly designated Series B Convertible Preferred ... expects to conduct a closing with respect to ...
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: